Dr. Tadashi Urashima is Performance and Digital Analytics Lead at GSK Japan. In this position, Dr. Urashima is responsible for leading digital transformation in Development and Medical Affairs. Also, Dr. Urashima has over 20 years’ experience in pharmaceutical company and has played roles in clinical development, project management, medical excellence, MSL Manager. Dr. Urashima is in charge of MA community lead and content committee in DIA Japan. He has organized DIA MA forum or DIA MA short course as program chairman. Dr. Urashima holds a PhD in regenerative medicine from Tottori University and has a certification of Associated Certified Coach (ACC) in International Coaching Federation.

Takeshi Shukunobe was born in 1968. Mr. Shukunobe bacame chronic nephritis when he was 3 years old and initiated dialysissince because of chronic renal failure when he was 18 years old. In 2008, his left kidney was removed in a nephrectomy because of kidney cancer. He is the physically handicapped and licensed social worker. Mr. Shukunobe left Sony Corporation which he had worked for 14 years, then obtained certificate on social worker and started buisiness, patienthood, in 2010. PPeCC,Inc. was started in 2019. Patienthood was merged into PPeCC,Inc. in 2020. He gives lecture and training based on his experience as a patient and has many connection with health care providers, health care companies, patient organizations and pateints.

Hideki Ninomiya graduated from the University of Tokyo's School of Medicine. After working as a neurosurgeon, he entered the world of data science. He engaged in medical information and telemedicine at Medley Inc. Afterwards, he started his own company, Datack Inc.

Dr. Yoshiyuki Sugimoto is the Scientifica Advisor in Medical Affairs at AbbVie Japan. Dr. Sugimoto graduated from Faculty of Pharmaceutical Sciences, the University of Tokyo in 1998 and completed Master's course at Graduate School of Pharmaceutical Science, the University of Tokyo in 2000. Dr. Sugimoto Joined Kyowa Hakko Kogyo Co., Ltd. (current Kyowa Kirin Co., Ltd.) in 2000, and moved to AbbVie Japan in 2016. Dr. Sugimoto has over 20 years’ experience in Pharmaceutical industry including Research, Development and Medical Affairs. Currently Dr. Sugimoto works for Rheumatology Medical Affairs Team and plays a leading role in the strategy of rheumatology field. Dr. Sugimoto obtained PhD degree from Waseda University in 2014.

2006: Joined Novartis Pharma K.K. Sales Department (MR) 2011: Worked as an MSL at Medical Affairs (cardiovascular and diabetes areas) 2016: Worked as a medical strategy and data creation at Medical Affairs Medical Scientific Expert Group (diabetes area) 2018: Worked as a group manager at Medical Affairs Scientific Communication Group (oncology area) 2019: Worked as a group manager of the MSL team at Medical Affairs MSL Group (cardiovascular area) 2021: Worked as a group manager at Medical Affairs Medical Scientific Expert Group (medical strategy, data creation, disease awareness, etc.) (cardiovascular and nephrological areas) Qualifications: Pharmacist license, MBA from Globis Business School (graduated in 2020)

Shuji Uno has served as Medical Lead at Medical Affairs department in BMS K.K. since July 2020. Shuji is responsible for Medical Plan development via UMNs identification and any activities of Evidence Generation in hematology area, such as company-sponsored studies, investigator-sponsored studies, and publication. He has over 8 years of experineces in Medical Affairs department including field work experiences as MSL in pharmaceutical industry. He holds a Ph.D. in life science from University of Tokyo.

Dr. Shinichi Nishiuma is Executive Officer, Chief Medical Officer at Aculys Pharma Inc. After graduating from Kobe University School of Medicine in 1997, he began his medical career as an internist and a gastroenterologist at Kobe City General Hospital. Recognizing issues with the drug lag for hepatitis C treatment, he took on the role of a physician in clinical development at Schering-Plough (now merged into MSD). Following that, he was responsible for clinical development and safety management at Eli Lilly Japan. From 2018, he served as the Head of Medical Division at Celgene Japan (now merged into BMS). In 2022, he became the Chief Medical Officer at Aculys Pharma Inc., where he remains to this day.

Yuta Kasai is a person in charge of Patient Engagement (PE) activity in Japan region in Clinical Operations at Astellas Pharma Inc (API). In this role, Yuta has been responsible for PE activity in clinical operations for about 5 years in Japan and supporting clinical trial team in terms of PE aspect such as collecting Japanese patient insight, dislosing clinical trial information to patient and relevant process mangaement. Yuta has also engaged in alignment with global PE acitivity as one of the member of a team leading PE acitivity in the global Clinical Operations at API and joined some industry activity such as JPMA, TransCelerate, and DIA to enhance Patient and Public Involvement in Japan with relenavt stakeholders.